Related Experiment Videos
[Adjuvant chemotherapy in rectal cancer]
1Abteilung Hämatologie/Onkologie, Medizinische Hochschule Hannover.
Summary
For rectal cancer patients with poor prognosis, combined adjuvant radio-chemotherapy significantly improves survival and reduces locoregional relapse. Continuous infusion 5-FU with irradiation further enhances these positive outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Context:
- Rectal carcinoma stages II and III (Dukes' B2 and C) present a poor prognosis with less than 50% 5-year survival.
- While adjuvant radiotherapy and chemotherapy offer benefits, their combined effect is crucial for improving outcomes.
Purpose:
- To evaluate the efficacy of combined adjuvant radio-chemotherapy in improving survival and reducing relapse rates for rectal cancer patients.
- To compare different chemoradiotherapy regimens, including continuous infusion 5-FU.
Summary:
- Adjuvant chemotherapy significantly reduces distant metastases and improves overall survival in rectal cancer.
- Combined adjuvant radio-chemotherapy, particularly with continuous infusion 5-FU, demonstrates a significant decrease in locoregional failure and distant metastases, leading to improved survival rates.
- Modern techniques in combined radio-chemotherapy (45-54 Gy, 5-FU) are considered the adjuvant treatment of choice for stage II and III rectal carcinoma.
Impact:
- Combined radio-chemotherapy significantly improves disease-free and overall survival for rectal cancer patients.
- A 50% reduction in locoregional relapse rates offers substantial benefits in quality of life.
- Continuous infusion 5-FU concurrent to irradiation represents a further advancement, decreasing failure rates and increasing survival.